Key result
NH29 acts as a nontoxin gating modifier that increases Kv7.2 currents, depresses evoked spike discharges in neurons, and dampens hippocampal glutamate and GABA release.
Population
Preclinical models including Kv7.2 channels, TRPV1 channels, and neurons
Design
Preclinical
Authors
Loading...
NH29 supports preclinical exploration of Kv7.2 modulation for hyperexcitability; clinical translation remains untested.
NH29 acts as a non-toxin gating modifier targeting the voltage-sensing domain of Kv7.2 channels, providing a structural framework for designing treatments for hyperexcitability disorders.
Peretz et al. (2010) studied Hyperexcitability disorders. NH29 was evaluated on Kv7.2 currents, spike discharges, and neurotransmitter release. NH29 acts as a nontoxin gating modifier that increases Kv7.2 currents, depresses evoked spike discharges in neurons, and dampens hippocampal glutamate and GABA release.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: